


DOCKET NO: 17293DIV(HL)



RECEIVED

AUG 19 2003

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1625  
# 11 E  
8-29-03  
Seaman

Applicant: Massaro et al

) Group Art Unit: 1625

Serial No.: 09/919,195

)

Conf. No. 4830

)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment-Fee; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Filed: July 31, 2001

)

For: METHODS AND  
COMPOSITIONS FOR THE  
TREATMENT AND PREVENTION  
OF LUNG DISEASE

)

Date of Deposit: 8/14/2003

Examiner: Seaman, Margaret

)

Person making Deposit: BONNIE FERGUSON

Signature: Bonnie Ferguson

Date of Signature: 8/14/2003

#### REPLY AND AMENDMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

This Reply is being filed in reply to the Office Action mailed March 19, 2003. Applicants have the following comments.

09/05/2003 DLYONS 00000003 010885 09919195

01 FC:1251 110.00 DA

09/05/2003 DLYONS 00000013 010885 09919195

01 FC:1252 300.00 DA

RECEIVED

Serial No.: 09/919,195; Conf. No. 4830  
Docket No.: 17293DIV  
Filed: July 31, 2001

AUG 19 2003

TECH CENTER 1600/2900

AMENDMENTS

1-12 (Cancelled)

13) (Currently amended) A method for the treatment or prevention of alveolar destruction in a mammal comprising the step of administering a therapeutically effective amount of an RAR  $\beta$  antagonist having specific RAR modulating activity to said mammal, and such antagonist is not specific to at least one other RAR receptor subtype.

14) (Original) The method of claim 13, wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .

15) (Original) The method of claim 13 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .

16) (Original) The method of claim 13 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .

17) (Original) The method of claim 13, wherein said composition is administered in the form of an inhalant.

18) (Original) The method of claim 17 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .

19) (Original) The method of claim 17 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .

20) (Original) The method of claim 17 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .

21) (Original) A method to increase the gas-exchange surface area of a mammalian lung in a mammal in need thereof comprising the step of administering a therapeutically effective amount of an RAR  $\beta$  antagonist having specific RAR modulating activity to said mammal.

22) (Original) The method of claim 21, wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .

23) (Original) The method of claim 21 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .

Serial No.: 09/919,195; Conf. No. 4830  
Docket No.: 17293DIV  
Filed: July 31, 2001

24) (Original) The method of claim 21 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .

25) (Original) The method of claim 21, wherein said composition is administered in the form of an inhalant.

26) (Original) The method of claim 25 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$ .

27) (Original) The method of claim 25 wherein said RAR $\beta$  antagonist is not specific to RAR $\gamma$ .

28) (Original) The method of claim 25 wherein said RAR $\beta$  antagonist is not specific to RAR $\alpha$  or RAR $\gamma$ .

*End*  
*Concl'd*  
29-30 (Cancelled)

---